XML 23 R12.htm IDEA: XBRL DOCUMENT v3.25.3
Earnings (Loss) per Share
 9 Months Ended
Nov. 01, 2025
Earnings Per Share [Abstract]  
Earnings (Loss) per Share Earnings (Loss) per Share
The computation of basic and diluted net earnings (loss) per common share attributable to common stockholders is (in thousands, except per share data):
 Three Months EndedNine Months Ended
 Nov 1, 2025Nov 2, 2024Nov 1, 2025Nov 2, 2024
Net earnings (loss) attributable to Guess?, Inc.$25,648 $(23,395)$(1,038)$(20,976)
Less net earnings attributable to nonvested restricted stockholders297 210 526 687 
Net earnings (loss) attributable to common stockholders25,351 (23,605)(1,564)(21,663)
Remove income related to the convertible senior notes1
— (7,712)— — 
Net earnings (loss) attributable to common stockholders used in diluted computations
$25,351 $(31,317)$(1,564)$(21,663)
Weighted average common shares used in basic computations51,586 50,798 51,487 52,047 
Effect of dilutive securities:
Stock options and restricted stock units1,583 — — — 
Convertible senior notes— 15,810 — — 
Weighted average common shares used in diluted computations53,169 66,608 51,487 52,047 
Net earnings (loss) per common share attributable to common stockholders:
Basic
$0.49 $(0.46)$(0.03)$(0.42)
Diluted
$0.48 $(0.47)$(0.03)$(0.42)
______________________________________________________________________
Notes:
1Expenses (income) related to the convertible senior notes include interest expense, loss on extinguishment of debt and (gain) loss on fair value remeasurement for embedded derivative, as applicable, net of associated income tax effect.
Certain potentially dilutive common stock, including certain equity awards granted that were outstanding as well as shares issuable under convertible senior notes, are not included in the computation of diluted weighted average common shares and potential common shares outstanding if their effect would have been
antidilutive. Antidilutive shares excluded from the computation of diluted weighted average common shares and potential common shares outstanding are:
 Three Months EndedNine Months Ended
 Nov 1, 2025Nov 2, 2024Nov 1, 2025Nov 2, 2024
Stock options and restricted stock units1
925,262 1,492,824 1,899,797 1,557,115 
Convertible senior notes (as converted)16,144,935 — 16,059,119 15,798,155 
Total17,070,197 1,492,824 17,958,916 17,355,270 
______________________________________________________________________
Notes:
1During the three months ended November 1, 2025, 925,262 potentially dilutive shares were excluded because the assumed proceeds resulted in these awards being antidilutive. During the nine months ended November 1, 2025, 806,599 potentially dilutive shares were excluded given the Company’s net loss and 1,093,198 potentially dilutive shares were excluded because the assumed proceeds resulted in these awards being antidilutive. During the three months ended November 2, 2024, 1,172,118 potentially dilutive shares were excluded given the Company’s net loss and 320,706 potentially dilutive shares were excluded because the assumed proceeds resulted in these awards being antidilutive. During the nine months ended November 2, 2024, 1,313,235 potentially dilutive shares were excluded given the Company’s net loss and 243,880 potentially dilutive shares were excluded because the assumed proceeds resulted in these awards being antidilutive.
Additionally, for the three and nine months ended November 1, 2025, the Company excluded 356,124 nonvested stock units which were subject to the achievement of performance-based or market-based vesting conditions from the computation of diluted weighted average common shares and potential common shares outstanding because these conditions were not achieved as of November 1, 2025. For the three and nine months ended November 2, 2024, the Company excluded 574,941 nonvested stock units which were subject to the achievement of performance-based or market-based vesting conditions from the computation of diluted weighted average common shares and potential common shares outstanding because these conditions were not achieved as of November 2, 2024.
There were no warrants related to the 2.00% convertible senior notes due April 2024 (the “2024 Notes”) outstanding as of November 1, 2025. Warrants related to the 2024 Notes to purchase approximately 0.3 million shares of the Company’s common shares at an adjusted strike price of $40.65 per share were outstanding as of November 2, 2024. Warrants related to the 3.75% convertible senior notes due April 2028 (the “2028 Notes,” and together with the 2024 Notes, the “Notes”) to purchase approximately 16.1 million and 15.8 million shares of the Company’s common shares at adjusted strike prices of $36.89 and $37.61 per share were outstanding as of November 1, 2025 and November 2, 2024, respectively. During the three and nine months ended November 1, 2025 and November 2, 2024, these warrants were excluded from the computation of diluted net earnings (loss) per share since the warrants’ strike prices were greater than the average market price of the Company’s common stock. See Note 11 - Convertible Senior Notes and Related Transactions for more information regarding the Notes and related hedge transactions.